Observing the natural progression of interstitial lung disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to collect data and blood samples from patients diagnosed with interstitial lung disease (ILD) as well as a control group for comparison. By analyzing these samples, researchers hope to describe the phenotypic expression of various forms of ILD, including idiopathic pulmonary fibrosis and sarcoidosis. The observational nature of the study allows for a comprehensive understanding of disease progression without any specific interventions. This data will contribute to a better understanding of ILD and its impact on patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Interstitial lung disease

Exclusion Criteria:

* Does not have Interstitial lung disease

Where it's running

• University of Chicago
  Chicago, Illinois, United States Recruiting

Study contacts

• Principal investigator: Mary E Strek, MD — University of Chicago
• Study coordinator: Vanita Patel, MPH
• Phone: 773-702-1012

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Biobank for interstitial lung diseases

  This study is setting up a collection of health information and samples from patients with interstitial lung diseases to help researchers learn more about the condition and find better treatments.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas · NCT05392881

• New IPF drug ORJ-001 tested in adults with IPF

  A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.

  Recruiting at 2 sites Phase 2 Oorja Bio, Inc. · Doral, Florida and 1 other locations · NCT07869147

• Nalbuphine ER for IPF-related chronic cough

  This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.

  Recruiting at 4 sites Phase 3 Trevi Therapeutics · Wilmington, Delaware and 3 other locations · NCT07868419

• Home-based pulmonary rehabilitation for interstitial lung disease

  This study tests a 6-week home-based pulmonary rehabilitation program to see if it improves breathing, exercise ability, and quality of life for people with fibrotic interstitial lung disease in India.

  Recruiting Post Graduate Institute of Medical Education and Research, Chandigarh · Chandigarh, Chandigarh · NCT07830602

• Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07820254

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.